Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Antares Pharma

Sort by

Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)

Thursday, March 20, 2014 · 12:02 pm

Read More

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

Wednesday, January 22, 2014 · 3:48 pm

Read More

Antares: An In-Depth Look at Otrexup and Re-iteration of My Buy Recommendation (ATRS: $4.45) (Paid Subscribers Only)

Tuesday, August 20, 2013 · 11:44 am

Read More

Antares’ Pipeline is Bursting with New Products; Vibex MTX is the Star (ATRS)

Tuesday, September 11, 2012 · 7:40 am

Read More

Antares: Settlement of Litigation on EpiPen is a Positive (AIS, $3.08)

Saturday, April 28, 2012 · 7:01 am

Read More

Vibex MTX is the Most Exciting Component of the Antares Investment Outlook (AIS, $2.74)

Wednesday, March 28, 2012 · 4:49 pm

Read More

The Promise of the Antares Pipeline is the Basis of my Buy Recommendation (AIS, $2.40)

Wednesday, January 25, 2012 · 12:44 pm

Read More

Antares Is Initated As A Buy Based On Broad, Promising Pipeline (AIS, $2.59)

Thursday, December 15, 2011 · 12:14 pm

Read More

Libi-Gel Phase III Trial Results Should Be Released Shortly (AIS, $2.73)

Thursday, December 15, 2011 · 10:44 am

Read More

Collaboration with Teva on Self-Injected Drugs Is the Major Driver of the Investment Thesis (AIS, $2.68)

Thursday, December 15, 2011 · 10:37 am

Read More

Approval of Anturol Is Significant Positive (AIS, $2.68)

Thursday, December 15, 2011 · 10:30 am

Read More

Anturol’s December 8th PDUFA Date Is Looming (AIS, $2.77)

Thursday, December 15, 2011 · 10:23 am

Read More

There are 12 reports on file.

« Back to Company Reports Index